Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Mostrar otras versiones (1)

Steven A Nielsen,1 Marguerite B McDonald,2 Parag A Majmudar31Nielsen Eye Center, Quincy, MA, USA; 2Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 3Chicago Cornea Consultants Hoffman Estates, IL, USABackground: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nielsen SA, McDonald MB, Majmudar PA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/d6b4bbe8a6784bbd8e8d01cbb62b490b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d6b4bbe8a6784bbd8e8d01cbb62b490b
record_format dspace
spelling oai:doaj.org-article:d6b4bbe8a6784bbd8e8d01cbb62b490b2021-12-02T00:03:54ZSafety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients1177-54671177-5483https://doaj.org/article/d6b4bbe8a6784bbd8e8d01cbb62b490b2013-01-01T00:00:00Zhttp://www.dovepress.com/safety-of-besifloxacin-ophthalmic-suspension-06-in-refractive-surgery--a11977https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Steven A Nielsen,1 Marguerite B McDonald,2 Parag A Majmudar31Nielsen Eye Center, Quincy, MA, USA; 2Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 3Chicago Cornea Consultants Hoffman Estates, IL, USABackground: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in laser-assisted in situ keratomileusis (LASIK) prophylactic antibiotic regimens.Methods: Retrospective surveillance of LASIK surgery cases where besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalmic solution 0.5% were prescribed as prophylactic medications. Surgeons from nine US surgical centers provided retrospective case information on surgical outcomes from consecutive cases and reported any adverse events related to the antibacterial used. The primary endpoint was the incidence of adverse drug reactions.Results: A total of 801 case reports (801 eyes; 534 besifloxacin, 267 moxifloxacin) were obtained. The mean (standard deviation [SD]) age at time of surgery was 36.1 (10.6) years. The mean (SD) duration of antibiotic treatment was 8.6 (2.2) days in the besifloxacin group and 8.0 (2.3) in the moxifloxacin group; daily dosing frequency was higher in the moxifloxacin group preoperatively, on the day of surgery, and postoperatively. There were no reports of adverse drug reactions for the 801 eyes in this surveillance. There were no differences between the besifloxacin and moxifloxacin treatment groups in rates of unexpected corneal findings (2.1% vs 1.5%, P = 0.949). The distribution of final visual acuity for the besifloxacin and moxifloxacin groups were similar (P = 0.793). Most cases had a final visual acuity of 20/20 or better.Conclusion: In this retrospective surveillance study, the prophylactic use of besifloxacin ophthalmic suspension 0.6% and moxifloxacin ophthalmic solution 0.5% in patients undergoing LASIK surgery was not associated with any adverse drug reactions.Keywords: Besivance, refractive surgery, adverse drug reactions LASIK, moxifloxacin ophthalmic solution 0.5%, ocular infection prophylaxisNielsen SAMcDonald MBMajmudar PADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 149-156 (2013)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Nielsen SA
McDonald MB
Majmudar PA
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
description Steven A Nielsen,1 Marguerite B McDonald,2 Parag A Majmudar31Nielsen Eye Center, Quincy, MA, USA; 2Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 3Chicago Cornea Consultants Hoffman Estates, IL, USABackground: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in laser-assisted in situ keratomileusis (LASIK) prophylactic antibiotic regimens.Methods: Retrospective surveillance of LASIK surgery cases where besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalmic solution 0.5% were prescribed as prophylactic medications. Surgeons from nine US surgical centers provided retrospective case information on surgical outcomes from consecutive cases and reported any adverse events related to the antibacterial used. The primary endpoint was the incidence of adverse drug reactions.Results: A total of 801 case reports (801 eyes; 534 besifloxacin, 267 moxifloxacin) were obtained. The mean (standard deviation [SD]) age at time of surgery was 36.1 (10.6) years. The mean (SD) duration of antibiotic treatment was 8.6 (2.2) days in the besifloxacin group and 8.0 (2.3) in the moxifloxacin group; daily dosing frequency was higher in the moxifloxacin group preoperatively, on the day of surgery, and postoperatively. There were no reports of adverse drug reactions for the 801 eyes in this surveillance. There were no differences between the besifloxacin and moxifloxacin treatment groups in rates of unexpected corneal findings (2.1% vs 1.5%, P = 0.949). The distribution of final visual acuity for the besifloxacin and moxifloxacin groups were similar (P = 0.793). Most cases had a final visual acuity of 20/20 or better.Conclusion: In this retrospective surveillance study, the prophylactic use of besifloxacin ophthalmic suspension 0.6% and moxifloxacin ophthalmic solution 0.5% in patients undergoing LASIK surgery was not associated with any adverse drug reactions.Keywords: Besivance, refractive surgery, adverse drug reactions LASIK, moxifloxacin ophthalmic solution 0.5%, ocular infection prophylaxis
format article
author Nielsen SA
McDonald MB
Majmudar PA
author_facet Nielsen SA
McDonald MB
Majmudar PA
author_sort Nielsen SA
title Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_short Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_full Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_fullStr Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_full_unstemmed Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
title_sort safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-lasik patients
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/d6b4bbe8a6784bbd8e8d01cbb62b490b
work_keys_str_mv AT nielsensa safetyofbesifloxacinophthalmicsuspension06inrefractivesurgeryaretrospectivechartreviewofpostlasikpatients
AT mcdonaldmb safetyofbesifloxacinophthalmicsuspension06inrefractivesurgeryaretrospectivechartreviewofpostlasikpatients
AT majmudarpa safetyofbesifloxacinophthalmicsuspension06inrefractivesurgeryaretrospectivechartreviewofpostlasikpatients
_version_ 1718403955688472576

Ejemplares similares